<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065648</url>
  </required_header>
  <id_info>
    <org_study_id>CSMC-2011-MR-02-01-NATIVE-Mos</org_study_id>
    <nct_id>NCT02065648</nct_id>
  </id_info>
  <brief_title>Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet</brief_title>
  <official_title>NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare non-contrast abdominal MR Angiogram (MRA) syngo NATIVE
      sequence performed on a 3T Verio Siemens magnet to a standard contrast-enhanced MRA performed
      as part of routine clinical care in patients with normal renal function to determine if the
      non-contrast NATIVE sequence is a viable alternative to contrast enhanced MRA in patients
      with renal insufficiency. There are no interventions--this is an observational study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the NATIVE sequence proves to be a viable alternative to contrast enhanced MRA it will
      provide imaging physicians with the diagnostic tool to assess vascular disease in patients
      with renal insufficiency without placing them at risk for additional co-morbidities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of non-contrast enhanced MRA sequence</measure>
    <time_frame>36 months</time_frame>
    <description>Compare non-contrast enhanced MRA images with contrast-enhanced MRA images.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Syngo NATIVE MRA</arm_group_label>
    <description>All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consenting patients referred for standard of care contrast-enhanced abdominal MR
        Angiography
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Over age 18 Signed informed consent Referred for standard of care MRA

        Exclusion Criteria:

        No contra-indications for MRI/MRA ie implants which could interfere with magnets Renal
        insufficiency which would preclude use of contrast-enhanced contrast for a standard of care
        MRA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rola Saouaf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franklin G. Moser, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Rola Saouaf, MD</investigator_full_name>
    <investigator_title>Director, Body and Cardiac MRI</investigator_title>
  </responsible_party>
  <keyword>MRA</keyword>
  <keyword>Syngo Native</keyword>
  <keyword>Gadolinium</keyword>
  <keyword>Non contrast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

